Sign In
Buy VERV
$11.13
+0 (+0%)
At Close: Oct 24, 2025
Verve Therapeutics Appoints Experienced Biotechnology Executive, Alexander G. “Bo” Cumbo, to its Board of Directors
10:30am, Monday, 13'th Jun 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medici
Verve Therapeutics to Participate in the 2022 Jefferies Healthcare Conference
10:30am, Wednesday, 01'st Jun 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medici
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
01:23pm, Tuesday, 10'th May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Pfizer Acquires Biohaven For $11B
Pfizer Inc (NYSE: PFE) will acquire Biohaven Pharmaceutical Hold
Verve Therapeutics Announces Clearance of First VERVE-101 Clinical Trial Application and Outlines Global Clinical Development Strategy; Reports First Quarter 2022 Financial Results
10:30am, Tuesday, 10'th May 2022 GlobeNewswire Inc.
Verve on Track to Begin Dosing HeFH Patients in New Zealand in Mid-2022 in a Phase 1 Clinical Trial with Initial Clinical Data Expected in 2023
Verve Therapeutics Reports Additional VERVE-101 and GalNAc-Lipid Nanoparticle Delivery Data in Non-Human Primates at TIDES USA 2022
10:30am, Monday, 09'th May 2022 GlobeNewswire Inc.
VERVE-101 Preclinical Data Package Supports Company’s Global Development Strategy and Regulatory Submissions for Clinical Trials in Patients with HeFH
Verve Therapeutics to Participate in Upcoming May Investor Conferences
10:30am, Wednesday, 04'th May 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicin
Verve Therapeutics to Participate in Upcoming May Investor Conferences
06:30am, Wednesday, 04'th May 2022
CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines
Verve Therapeutics Presents Comprehensive Analyses of Off-target Editing Risk for VERVE-101 at Precision Genome Engineering Keystone Symposia
10:30am, Tuesday, 26'th Apr 2022 GlobeNewswire Inc.
Extensive Analyses in Multiple Human Cell Types Demonstrate Minimal to No Off-target Editing Following VERVE-101 Treatment, Supporting its Planned Clinical Initiation in 2022
Verve Therapeutics: Early-Stage Biotech With A Large Market
12:31am, Saturday, 16'th Apr 2022
Verve Therapeutics is a biotechnology company with a vision to provide cutting-edge solutions to cardiovascular diseases. The company is dedicated to creating genetic therapies to confer protection ag
Verve Therapeutics Reports Durable and Well-Tolerated Editing of ANGPTL3 Gene Out to More than 20 Months in Non-Human Primates for Potential Treatment of Atherosclerotic Cardiovascular Disease
10:30am, Monday, 04'th Apr 2022 GlobeNewswire Inc.
Updated Sequential Dosing Data Show Administration of PCSK9 Base Editor Followed by ANGPTL3 Base Editor is Well-Tolerated in NHPs
Verve Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Conference
10:30am, Thursday, 24'th Mar 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medic
Company News for Mar 15, 2022
01:27pm, Tuesday, 15'th Mar 2022 Zacks Investment Research
Companies In The News Are: BLDP, GOL, VERV, PFE.
Verve Therapeutics GAAP EPS of -$0.65 misses by $0.12
10:36am, Monday, 14'th Mar 2022 Seeking Alpha
Verve Therapeutics press release (VERV): Q4 GAAP EPS of -$0.65 misses by $0.12.Cash, Cash Equivalents and Marketable Securities of $360.4 Million with Cash Runway into 2024
Verve Therapeutics to Present at the Cowen 42nd Annual Healthcare Conference
11:30am, Wednesday, 23'rd Feb 2022 GlobeNewswire
CAMBRIDGE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics , a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will present at the Cowen 42 nd Annual Healthcare Conference on Tuesday, March 8, 2022 at 9:10 a.m. ET.
Verve Therapeutics to Present at the Cowen 42nd Annual Healthcare Conference
06:30am, Wednesday, 23'rd Feb 2022
CAMBRIDGE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicine
